## **EDITORIAL**

Dear friends and colleagues,

Heart failure (HF) is a progressive disorder associated with impaired quality of life, high morbidity, mortality and frequent hospitalization and affects millions of people from all around the world. Despite further improvements in HF therapy, mortality and morbidity remains to be very high. The life-long treatment, frequent hospitalization, and sophisticated and very expensive device therapies for HF also leads a substantial economic burden on the health care system. Therefore, implementation of evidence-based guideline-recommended therapy is very important to overcome its worse clinical outcomes. However, HF therapy is a long process that has many drawbacks and sometimes HF guidelines cannot answers to every question which rises in everyday clinical practice.

In this paper, commonly encountered questions, overlooked points, controversial issues, new drugs, management strategies in grey zone and problems arising during follow up of a HF patient in real life clinical practice have been addressed in the form of expert opinions based on the available data in the literature. The present work as an initiative of Heart Failure Working Group of Turkish Society of Cardiology was written by the authors who have a broad range of expertise and experience in the field of heart failure. This document is mainly focused on the pharmacological treatment rather than device therapy and intended for cardiologists, internists, cardiology trainees, general practitioners and nurses.

We hope you find this supplement useful in the management of heart failure in your daily clinical practice.

Lale Tokgözoğlu President of Turkish Society of Cardiology Hacettepe University, Faculty of Medicine, Cardiology Department, Ankara-*Turkey* 

Yüksel Çavuşoğlu
Past President of Working Group on Heart Failure of Turkish
Society of Cardiology
Eskişehir Osmangazi University, Faculty of Medicine,
Cardiology Department, Eskişehir-*Turkey* 

